Physician profile
Ming Yin
NPI 1255630505
$1,989.11
in general payments reported to CMS, 2019-2025
36 companies · $916 in 2025
The $916 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.63 · 2020: $11.50 · 2022: $16.63 · 2023: $201 · 2024: $829 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918 · Education: $28.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.70 |
| Education | $28.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $192.04 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $155.86 | 2023-2025 | |
| Daiichi Sankyo INC. | $138.35 | 2024-2025 | Enhertu, Injectafer |
| Eisai INC. | $117.12 | 2023-2025 | |
| Coherus Oncology, INC. | $116.86 | 2023-2025 | Loqtorzi, Udenyca |
| E.R. Squibb & Sons, L.L.C. | $114.98 | 2024-2025 | Opdivo, Krazati, Opdualag |
| Pfizer INC. | $99.25 | 2019-2025 | |
| Gilead Sciences, INC. | $91.71 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $88.98 | 2024-2025 | Rybrevant, Carvykti |
| Genentech USA, INC. | $85.10 | 2024-2025 | Phesgo, Perjeta, Alecensa |
| Celgene Corporation | $72.81 | 2024-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $65.67 | 2024-2025 | |
| Incyte Corporation | $62.59 | 2024-2025 | Zynyz, Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $46.96 | 2025 | Calquence, Lynparza |
| Adc Therapeutics America, INC. | $42.77 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $41.54 | 2025 | Zoladex, Xermelo |
| Genzyme Corporation | $39.50 | 2024 | |
| Genmab U.S., INC. | $34.43 | 2024 | Tivdak |
| Aveo Pharmaceuticals, INC. | $30.97 | 2023 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $30.14 | 2025 | Fruzaqla |
| Stemline Therapeutics INC. | $29.69 | 2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.01 | 2025 | |
| Taiho Oncology, INC. | $27.13 | 2025 | |
| Beone Medicines USA, INC. | $26.23 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $26.16 | 2024 | Libtayo |
| Deciphera Pharmaceuticals INC. | $25.97 | 2024 | Qinlock |
| Acrotech Biopharma INC. | $21.44 | 2024 | Beleodaq |
| Abbvie INC. | $21.22 | 2025 | |
| Immunocore Limited | $20.05 | 2025 | Kimmtrak |
| Glaxosmithkline, LLC. | $18.23 | 2023 | Ojjaara |
| Seagen INC. | $17.65 | 2023 | Tukysa |
| Pharmacosmos Therapeutics INC. | $15.82 | 2024 | Cosela |
| Beigene USA, INC. | $15.22 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $14.85 | 2025 | Ultomiris |
| Morphosys, US INC. | $12.81 | 2023 | Monjuvi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Yin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.